Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1857-1869

  Petraitis, Vidmantas ^a   Petraitiene, Ruta ^a   Groll, Andreas H ^a   Roussillon, Kristin ^a   Hemmings, Melissa ^a   Lyman, Caron A ^a   Sein, Tin ^a   Bacher, John ^a   Bekersky, Ihor ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CEFTAZIDIME; GENTAMICIN; MICAFUNGIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; CANDIDIASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; LUNG ASPERGILLOSIS; LUNG INFARCTION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CANDIDIASIS; LIPOPROTEINS; LUNG; MANNANS; NEUTROPENIA; ORGAN SIZE; PEPTIDES, CYCLIC; RABBITS;

EID: 0036093584     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1857-1869.2002     Document Type: Article

References (43)

1. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
2. FK 463
3. Role of small G proteins in yeast cell polarization and wall biosynthesis
4. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus
5. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer
6. Chlamydospore-like cells of Candida albicans in the gastrointestinal tract of infected, immunocompromised mice
7. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection
8. The evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy
9. Importance of antifungal drug-resistance: Clinical significance and need for novel therapy
10. Update on antifungals targeted to the cell wall: Focus on beta-1,3-glucan synthase inhibitors
11. Clinical pharmacology of antifungal agents
12. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin-like lipopeptide FK463 in rabbits
13. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
14. FK-463
15. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis
16. Evaluation of endpoints for antifungal susceptibility determinations with LY303366
17. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase
18. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
19. Efficacy of FK463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice
20. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis
21. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide
22. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
23. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors
24. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: A 9-year study
25. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths
26. Resistance of Candida species to fluconazole
27. Efficacy of amphotericin B encapsulated in liposome (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
28. Amphotericin B: Still the 'gold standard' for antifungal therapy
29. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis
30. Rat monoclonal antibodies against Aspergillus galactomannan
31. In vitro activities of a new lipopeptide antifungal agent. FK463, against a variety of clinically important fungi
32. FK463, a novel water-soluble echinocandin lipopeptide: Synthesis and antifungal activity
33. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens
34. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
35. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans
36. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
37. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits
38. The antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-β-glucan synthase inhibitor, during continuous versus intermittent infusion of cilofungin in treatment of experimental disseminated candidiasis
39. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations